Table 5 |
||||||||
|
Serotype distribution among pneumococcal strains displaying resistance to at least one antibiotic class (n = number of strains, % = percent of strains per geographic region). |
||||||||
|
Athens (n, %) |
Halkida (n, %) |
Thessaloniki (n, %) |
Ioannina (n, %) |
Alexandroupolis (n, %) |
Herakleion (n, %) |
Peloponnese (n, %) |
Total (n,%) |
|
|
|
||||||||
|
PCV7* serotypes |
80 (70.17) |
42 (73.68) |
33 (58.92) |
10 (76.92) |
6 (54.55) |
25 (75.76) |
30 (90.91) |
226 (71.29) |
|
19F |
32 (28.07) |
20 (35.09) |
9 (16,07) |
2 (15.38) |
3 (27.27) |
11 (33.33) |
10 (30.3) |
87 (27.44) |
|
14 |
10 (8.77) |
6 (10.53) |
10 (17.86) |
11 (33.33) |
3 (9.09) |
40 (12.62) |
||
|
9V |
20 (17.54) |
2 (3.57) |
2 (15.38) |
10 (30.3) |
34 (10.73) |
|||
|
23F |
10 (8.77) |
6 (10.53) |
6 (10.71) |
5 (38.46) |
1 (9.09) |
1 (3.04) |
4 (12.13) |
33 (10.41) |
|
6B |
8 (7.02) |
10 (17.54) |
5 (8.93) |
1 (7.69) |
2 (18.18) |
2 (6.06) |
2 (6.06) |
30 (9.46) |
|
18C |
1 (1.79) |
1 (3.03) |
2 (0.63) |
|||||
|
|
||||||||
|
PCV7-related serotypes |
17 (14.92) |
10 (17.55) |
11 (19.66) |
0 |
2 (18.18) |
4 (12.12) |
0 |
43 (13.56) |
|
6A |
7 (6.14) |
3 (5.26) |
5 (8.93) |
0 |
2 (6.06) |
17 (5.36) |
||
|
Other related |
10 (8.78) |
7 (12.29) |
6 (10.73) |
2 (18.18) |
2 (6.06) |
26 (8,20)) |
||
|
|
||||||||
|
Non PCV7 serogroups |
10 (8.77) |
3 (5.26) |
8 (14.28) |
3 (23.08) |
1 (9.09) |
2 (6.06) |
3 (9.09) |
32 (10.1) |
|
|
||||||||
|
Nontypeable strains |
7 (6.14) |
2 (3.51) |
4 (7.14) |
0 |
2 (18.18) |
2 (6.06) |
0 |
16 (5.05) |
|
|
||||||||
|
Total |
114 (100) |
57 (100) |
56 (100) |
13 (100) |
11 (100) |
33 (100) |
33 (100) |
317 (100) |
|
|
||||||||
|
*PCV7: heptavalent pneumococcal conjugate vaccine |
||||||||
|
Katsarolis et al. BMC Infectious Diseases 2009 9:120 doi:10.1186/1471-2334-9-120 |
||||||||
